{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:08:50Z","timestamp":1789578530511,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02615-6","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T08:29:51Z","timestamp":1739003391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ingenol mebutate in cancer therapy: mechanisms, clinical applications and future directions"],"prefix":"10.1007","volume":"42","author":[{"given":"Ndapewoshali F.","family":"Shafombabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Knott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrina","family":"Kapewangolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Sharifi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Calina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"2615_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2615_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11101-011-9212-6","volume":"14","author":"SJ Greay","year":"2015","unstructured":"Greay SJ, Hammer KA. Recent developments in the bioactivity of mono-and diterpenes: anticancer and antimicrobial activity. Phytochem Rev. 2015;14:1\u20136.","journal-title":"Phytochem Rev"},{"key":"2615_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s13555-014-0061-2","volume":"4","author":"DR Alchin","year":"2014","unstructured":"Alchin DR. Ingenol mebutate: A succinct review of a succinct therapy. Dermatol Ther (Heidelb). 2014;4:157\u201364.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2615_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1440-0960.1988.tb00383.x","volume":"29","author":"AC Green","year":"1988","unstructured":"Green AC, Beardmore GL. Home treatment of skin cancer and solar keratoses. Australas J Dermatol. 1988;29:127\u201330.","journal-title":"Australas J Dermatol"},{"key":"2615_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13555-012-0008-4","volume":"2","author":"FR Ali","year":"2012","unstructured":"Ali FR, Wlodek C, Lear JT. The role of IMin the treatment of actinic keratoses. Dermatol Ther. 2012;2:8.","journal-title":"Dermatol Ther"},{"key":"2615_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/ijms19010263","volume":"19","author":"AML Seca","year":"2018","unstructured":"Seca AML, Pinto D. Plant secondary metabolites as anticancer agents: successes in clinical trials and therapeutic application. Int J Mol Sci. 2018;19:263.","journal-title":"Int J Mol Sci"},{"key":"2615_CR7","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-03-2837","volume":"64","author":"SM Ogbourne","year":"2004","unstructured":"Ogbourne SM, Suhrbier A, Jones B, Cozzi S-J, Boyle GM, Morris M, McAlpine D, Johns J, Scott TM, Sutherland KP, Gardner JM, Le TTT, Lenarczyk A, Aylward JH, Parsons PG. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64:2833\u20139.","journal-title":"Cancer Res"},{"key":"2615_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-018-0343-8","author":"SA Braun","year":"2018","unstructured":"Braun SA, Baran J, Schrumpf H, Buhren BA, Bolke E, Homey B, Gerber PA. IMinduces a tumor cell-directed inflammatory response and antimicrobial peptides thereby promoting rapid tumor destruction and wound healing. Eur J Med Res. 2018. https:\/\/doi.org\/10.1186\/s40001-018-0343-8.","journal-title":"Eur J Med Res"},{"key":"2615_CR9","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/bjd.19330","volume":"183","author":"MF Mohd Mustapa","year":"2020","unstructured":"Mohd Mustapa MF, De Berker D, Mcgregor JM, Exton LS, Hughes BR, Levell NJ. Suspension of marketing authorization for ingenol mebutate. Br J Dermatol. 2020;183:792.","journal-title":"Br J Dermatol"},{"key":"2615_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/pca.2711","volume":"29","author":"T B\u00e9res","year":"2018","unstructured":"B\u00e9res T, Dragull K, Posp\u00ed\u0161il J, Tarkowsk\u00e1 D, Dan\u010d\u00e1k M, B\u00edba O, Tarkowski P, Dole\u017eal K, Strnad M. quantitative analysis of ingenol in Euphorbia species via validated isotope dilution ultra-high performance liquid chromatography tandem mass spectrometry. Phytochem Anal. 2018;29:23\u20139.","journal-title":"Phytochem Anal"},{"key":"2615_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13555-016-0137-2","volume":"6","author":"M Bertelsen","year":"2016","unstructured":"Bertelsen M, Stahlhut M, Grue-S\u00f8rensen G, Liang X, Christensen GB, Skak K, Engell KM, H\u00f6gberg T. Ingenol disoxate: A novel 4-Isoxazolecarboxylate ester of ingenol with improved properties for treatment of actinic keratosis and other non-melanoma skin cancers. Dermatol Ther (Heidelb). 2016;6:599\u2013626.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2615_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3390\/cells10050987","volume":"10","author":"U Sumarni","year":"2021","unstructured":"Sumarni U, Reidel U, Eberle J. Targeting cutaneous T-cell lymphoma cells by IM(PEP005) correlates with pkc\u03b4 activation, ros induction as well as downregulation of XIAP and c-FLIP. Cells. 2021;10:987.","journal-title":"Cells"},{"key":"2615_CR13","doi-asserted-by":"publisher","first-page":"5624","DOI":"10.1016\/j.bmcl.2013.08.038","volume":"23","author":"X Liang","year":"2013","unstructured":"Liang X, Grue-Sorensen G, Mansson K, Vedso P, Soor A, Stahlhut M, Bertelsen M, Engell KM, Hogberg T. Syntheses, biological evaluation and SAR of IManalogues for treatment of actinic keratosis and non-melanoma skin cancer. Bioorganics Med Chem Lett. 2013;23:5624\u20139.","journal-title":"Bioorganics Med Chem Lett"},{"key":"2615_CR14","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2147\/TCRM.S145779","volume":"14","author":"N Skroza","year":"2018","unstructured":"Skroza N, Bernardini N, Proietti I, Potenza C. Clinical utility of IMin the management of actinic keratosis: perspectives from clinical practice. Ther Clin Risk Manag. 2018;14:1879\u201385.","journal-title":"Ther Clin Risk Manag"},{"key":"2615_CR15","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1517\/14740338.2015.1108962","volume":"14","author":"B Berman","year":"2015","unstructured":"Berman B. Safety and tolerability of IMin the treatment of actinic keratosis. Expert Opin Drug Saf. 2015;14:1969\u201378.","journal-title":"Expert Opin Drug Saf"},{"key":"2615_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11418-023-01682-1","volume":"77","author":"F Kikuyama","year":"2023","unstructured":"Kikuyama F, Suzuki S, Jibiki A, Yokoyama Y, Kawazoe H, Kitanaka S, Nakamura T. IMinhibits the growth of pancreatic cancer cells in vitro via STING with an efficacy comparable to that of clinically used anticancer agents. J Nat Med. 2023;77:343\u201351.","journal-title":"J Nat Med"},{"key":"2615_CR17","doi-asserted-by":"publisher","first-page":"116134","DOI":"10.1016\/j.taap.2022.116134","volume":"449","author":"Y-Y Hsieh","year":"2022","unstructured":"Hsieh Y-Y, Cheng Y-W, Wei P-L, Yang P-M. Repurposing of IMfor treating human colorectal cancer by targeting S100 calcium-binding protein A4 (S100A4). Toxicol Appl Pharmacol. 2022;449:116134.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2615_CR18","doi-asserted-by":"publisher","first-page":"e0153975","DOI":"10.1371\/journal.pone.0153975","volume":"11","author":"TT Le","year":"2016","unstructured":"Le TT, Skak K, Schroder K, Schroder WA, Boyle GM, Pierce CJ, Suhrbier A. IL-1 contributes to the anti-cancer efficacy of Ingenol mebutate. PLoS ONE. 2016;11:e0153975.","journal-title":"PLoS ONE"},{"key":"2615_CR19","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1186\/s40064-016-2290-6","volume":"5","author":"I Bobyr","year":"2016","unstructured":"Bobyr I, Campanati A, Consales V, Giuliodori K, Scalise A, Offidani A. Efficacy, safety and tolerability of field treatment of actinic keratosis with IM0.015% gel: a single center case series. Springerplus. 2016;5:627.","journal-title":"Springerplus"},{"key":"2615_CR20","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1158\/1535-7163.MCT-15-0023-T","volume":"14","author":"SN Freiberger","year":"2015","unstructured":"Freiberger SN, Cheng PF, Iotzova-Weiss G, Neu J, Liu Q, Dziunycz P, Zibert JR, Dummer R, Skak K, Levesque MP, Hofbauer GF. IMSignals via PKC\/MEK\/ERK in keratinocytes and induces interleukin decoy receptors IL1R2 and IL13RA2. Mol Cancer Ther. 2015;14:2132\u201342.","journal-title":"Mol Cancer Ther"},{"key":"2615_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2010.12.038","volume":"66","author":"RH Rosen","year":"2012","unstructured":"Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of IMgel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66:486\u201393.","journal-title":"J Am Acad Dermatol"},{"key":"2615_CR22","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1021\/acscentsci.7b00420","volume":"3","author":"CG Parker","year":"2017","unstructured":"Parker CG, Kuttruff CA, Galmozzi A, J\u00f8rgensen L, Yeh C-H, Hermanson DJ, Wang Y, Artola M, McKerrall SJ, Josyln CM, N\u00f8rremark B, D\u00fcnstl G, Felding J, Saez E, Baran PS, Cravatt BF. Chemical proteomics identifies SLC25A20 as a functional target of the ingenol class of actinic keratosis drugs. ACS Cent Sci. 2017;3:1276\u201385.","journal-title":"ACS Cent Sci"},{"key":"2615_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2310\/7750.2012.12050","volume":"17","author":"AK Gupta","year":"2013","unstructured":"Gupta AK, Paquet M. Ingenol mebutate: A promising treatment for actinic k\u00e9ratoses and nonmelanoma skin cancers. J Cutan Med Surg. 2013;17:173\u20139.","journal-title":"J Cutan Med Surg"},{"key":"2615_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaad.2012.09.050","volume":"68","author":"G Martin","year":"2013","unstructured":"Martin G, Swanson N. Clinical findings using IMgel to treat actinic keratoses. J Am Acad Dermatol. 2013;68:39\u201348.","journal-title":"J Am Acad Dermatol"},{"key":"2615_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4103\/2229-5178.115538","volume":"4","author":"S Aditya","year":"2013","unstructured":"Aditya S, Gupta S. Ingenol mebutate: A novel topical drug for actinic keratosis. Indian Dermatol Online J. 2013;4:246\u20139.","journal-title":"Indian Dermatol Online J"},{"key":"2615_CR26","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1158\/0008-5472.CAN-09-4303","volume":"70","author":"L Li","year":"2010","unstructured":"Li L, Shukla S, Lee A, Al E. The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res. 2010;70:4509\u201319.","journal-title":"Cancer Res"},{"key":"2615_CR27","doi-asserted-by":"publisher","first-page":"8123","DOI":"10.4049\/jimmunol.177.11.8123","volume":"177","author":"JM Challacombe","year":"2006","unstructured":"Challacombe JM, Suhrbier A, Parsons PG, Al E. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol. 2006;177:8123\u201332.","journal-title":"J Immunol"},{"key":"2615_CR28","doi-asserted-by":"publisher","first-page":"965.e1","DOI":"10.1016\/j.jaad.2013.12.045","volume":"70","author":"G Micali","year":"2014","unstructured":"Micali G, Lacarrubba F, Nasca MR, Schwartz RA. Topical pharmacotherapy for skin cancer. J Am Acad Dermatol. 2014;70:965.e1-965.e12.","journal-title":"J Am Acad Dermatol"},{"key":"2615_CR29","unstructured":"RXLIST. Picato.  https:\/\/www.rxlist.com\/picato-drug.htm#description"},{"key":"2615_CR30","first-page":"633","volume":"64","author":"JR Ramsay","year":"2011","unstructured":"Ramsay JR, Suhrbier A, Aylward JH, Ogbourne S, Cozzi SJ, Poulsen MG, Baumann KC, Welburn P, Redlich GL, Parsons PG. The sap from Euphorbia peplusis effective against human nonmelanoma skin cancers. Br J Dermatol. 2011;64:633\u20136.","journal-title":"Br J Dermatol"},{"key":"2615_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s13555-014-0051-4","volume":"4","author":"M Mansuy","year":"2014","unstructured":"Mansuy M, Nikkels-Tassoudji N, Arrese JE, Rorive A, Nikkels AF. Recurrent in situ melanoma successfully treated with ingenol mebutate. Dermatol Ther. 2014;4:131\u20135.","journal-title":"Dermatol Ther"},{"key":"2615_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/toxins2010174","volume":"2","author":"E Ersvaer","year":"2010","unstructured":"Ersvaer E, Olsnes KA, Hampson P, Al E. The protein kinase C agonist PEP005 (Ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity. Toxins. 2010;2:174\u201394.","journal-title":"Toxins"},{"key":"2615_CR33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1590\/abd1806-4841.20186982","volume":"93","author":"MIR Saraiva","year":"2018","unstructured":"Saraiva MIR, Portocarrero LKL, Vieira M, Swiczar BCC, Westin AT. IMin the treatment of actinic keratoses: clearance rate and adverse effects. An Bras Dermatol. 2018;93:529\u201334.","journal-title":"An Bras Dermatol"},{"key":"2615_CR34","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1056\/NEJMoa1811850","volume":"380","author":"MHE Jansen","year":"2019","unstructured":"Jansen MHE, Kessels JPHM, Nelemans PJ, Kouloubis N, Arits AHMM, Pelt HPAV, Quaedvlieg PJF, Essers BAB, Steijlen PM, Kelleners-Smeets NWJ, Mosterd K. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med. 2019;380:935\u201346.","journal-title":"N Engl J Med"},{"key":"2615_CR35","unstructured":"Agency, EM. 2020. EMA suspends Picato as a precaution while review of skin cancer risk continues. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_en.pdf Accessed 17 Jan 2020."},{"key":"2615_CR36","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/14740338.2021.1915280","volume":"20","author":"EAT Koch","year":"2021","unstructured":"Koch EAT, Wessely A, Steeb T, Berking C, Heppt MV. Safety of topical interventions for the treatment of actinic keratosis. Expert Opin Drug Saf. 2021;20:801\u201314.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02615-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02615-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02615-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T14:25:38Z","timestamp":1741271138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02615-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["2615"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02615-6","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"69"}}